Showing results (131-140 of 154) with videos related to
Sort By:
Pageof 16
Journal of Gynecologic Oncology|March 21, 2025
Revision of quality indicators for cervical cancer and trend analysis of existing indicators in JapanTamaki Kakuwa, Ryoko Rikitake, Satoru Nagase, et al.Genes|October 19, 2016
Methylation Analysis of DNA Mismatch Repair Genes Using DNA Derived from the Peripheral Blood of Patients with Endometrial Cancer: Epimutation in Endometrial CarcinogenesisTakashi Takeda, Kouji Banno, Megumi Yanokura, et al.Acta Obstetricia Et Gynecologica Scandinavica|November 21, 2012
Preoperative and intraoperative assessment of myometrial invasion in endometrial cancer: comparison of magnetic resonance imaging and frozen sectionsIori Kisu, Kouji Banno, Li-Yu Lin, et al.Cancer Science|May 25, 2022
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775Kan Yonemori, Mayu Yunokawa, Kimio Ushijima, et al.International Journal of Clinical Oncology|November 22, 2017
Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancerToshiaki Saito, Tsutomu Tabata, Hitoshi Ikushima, et al.Scientific Reports|June 29, 2026
Elimusertib exhibits strong synergy with olaparib in ovarian cancer organoids through replication fork interferenceMio Takahashi, Aki Ookubo, Takuma Yoshimura, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 20, 2015
Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancersYusuke Kobayashi, Kanako Nakamura, Hiroyuki Nomura, et al.The Keio Journal of Medicine|June 22, 2025
The Keio HBOC Center: A Model of Hereditary Breast and Ovarian Cancer ManagementYusuke Kobayashi, Kenta Masuda, Tomoko Seki, et al.Journal of Gynecologic Oncology|May 13, 2022
TP53 variants in p53 signatures and the clonality of STICs in RRSO samplesTomoko Akahane, Kenta Masuda, Akira Hirasawa, et al.Journal of Gynecologic Oncology|July 1, 2025
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trialShin Nishio, Tadaaki Nishikawa, Masahiko Mori, et al.Pageof 16